PresentationPDF Available

Kelsey wallace 2.0 APOC 2019 RG

Authors:

Abstract

APOC 2019 presentation
!"#$%&%$'()*$+),%-&-.')
/01)2#"+"#3/$%-0
456!78865)9):;<*8:),)9;==;>7)
?5 @:6<;8)9)A7=87B
Robison & Hudson Nature Review 2014
8C-$$%+D)>/0C"#)%0C%1"0C")#/$"+E)FGGHIJK
-
!"#"
$""#"
$!"#"
%""#"
%!"#"
&""#"
&!"#"
%""' %""( %"") %"$" %"$$ %"$% %"$& %"$* %"$! %"$+
WASR%per%million
,-./0123
4563789259/2
LI'"/#)+M#3%3/&)NCD%&1#"0E)FGGKIFGJL)
O8C-$&/01P
ICCC Diagnostic
Grouping
Number of
cases analysed
%
Number of
cases
analysed
%
Leukaemias, myeloproliferative diseases, and myelodysplastic diseases 186 86.0 201 92. 7
- Lymphoid leukaemias 140 89.3 170 93. 8
- Other leukaemias 47 74.5 31 87. 1
Lymphomas and reticuloendothelial neoplasms 46 91.3 55 98. 2
CNS and miscellaneous intracranial and intraspinal neoplasms 159 76.7 167 76.8
Neuroblastoma and other peripheral nervous cell tumours 42 66.7 36 70. 6
Retinoblastoma 12 100.0 19 100. 0
Renal tumours 30 90.0 29 89.1
Hepatic tumours7 6x11 x
Malignant bone tumours 28 71.4 29 67. 8
Soft tissue and other extraosseous sarcomas 34 73.5 43 65.8
Germ cell tumours, trophoblastic tumours and neoplasms of gonads 14 85.7 12 81.5
Other malignant epithelial neoplasms and malignant melanomas 16 93.8 25 100.0
ALL DIAGNOSES COMBINED 571 81.6 633 84.5
2011-2015
2006-2010
LI'"/#)+M#3%3/&)N'-M0.)2"-2&"E)
FGGKIFGJL)O8C-$&/01P
Birch-
Alston
Diagnostic
Grouping
Number of
cases
analysed
Number of
cases
analysed
2006-2010
2011-2015
*+)$D"#")/)Q"#$%&%$')1"Q%C%$)
Q-#)'-M0.)Q"R/&"+)SD-)
D/3")T""0)+MCC"++QM&&')
$#"/$"1)Q-#)C/0C"#U
9D/$)%+)$D")/C$M/&)%R2/C$)-Q)C/0C"#)
/01)%$+)$#"/$R"0$)-0)$D")CD/0C")-Q)
D/3%0.)/)T/T'U
o8C-$&/01)D/+)/CCM#/$")1/$/T/+"+)-Q)C/0C"#)
1%/.0-+%+)/01)2#".0/0C'
o9")D/3")&%0V"1)$D"R)$-)."$)/)C-R2&"$")
2%C$M#")-Q)$D")%R2/C$)-Q)/)C/0C"#)1%/.0-+%+
o;&&)/."+)M2)$-)WGE)JXYJIFGJW
oFZEFGJ)S-R"0)S%$D)C/0C"#
;01"#+-0)5;)"$)/&[)
:MR/0 5"2#-1MC$%-0)ZZOHP()JFYJIJFXGE)
1-%(JG[JGXZ\DMR#"2\1"'FJK
4#".0/0C')/Q$"#)C/0C"#)I
S-R"0)0-$)2#".0/0$)T"Q-#")C/0C"#
63"#/&&()KEKFH)-T+"#3"1)3+)
JGEHZK)"]2"C$"1)
2#".0/0C%"+
C/0C"#)+M#3%3-#+)S"#")
ZY^)&"++)&%V"&')$-)/CD%"3")
/)2#".0/0C')
/Q$"#)
1%/.0-+%+)$D/0)S-R"0)%0)
$D")."0"#/&)2-2M&/$%-0)
;01"#+-0)5;)"$)/&[)
:MR/0 5"2#-1MC$%-0)ZZOHP()JFYJIJFXGE)
1-%(JG[JGXZ\DMR#"2\1"'FJK
4#".0/0C')/Q$"#)C/0C"#)%0).%#&+)/01)
S-R"0)%0)8C-$&/01()
/)2-2M&/$%-0IT/+"1)/0/&'+%+
;01"#+-0)5;)"$)/&[)
:MR/0 5"2#-1MC$%-0)ZZOHP()JFYJIJFXGE)
1-%(JG[JGXZ\DMR#"2\1"'FJK
@D")CD/0.%0.)#%+V)$-)Q"#$%&%$')
%0)+-R")C/0C"#+
0
0.2
0.4
0.6
0.8
1
Hodgkin lymphoma
Leukaemia
Brain/CNS
1981-1988
1989-1996
1997-2004
2005-2012
;01"#+-0)5;)"$)/&[)
:MR/0 5"2#-1MC$%-0)ZZOHP()JFYJIJFXGE)
1-%(JG[JGXZ\DMR#"2\1"'FJK
5"2#-1MC$%-0)/R-0.)R/&")+M#3%3-#+)-Q)
C/0C"#()
/)0/$%-0/&)_-#S".%/0)C-D-#$)+$M1')
;&&)</&"+)JXKLIYL)Q-&&-S"1)$-)FGJW
</&")C/0C"#)+M#3%3-#+)O0)`)FKYHP)D/1)#"1MC"1)2/$"#0%$')
O:5()G[HFE)XL^)C-0Q%1"0C")%0$"#3/&)O>*P()G[KYNG[HKP[)
@D%+)S/+)R-+$)/22/#"0$)%0)+M#3%3-#+)-Q)$"+$%CM&/#)C/0C"#E)
T#/%0)$MR-M#+E)&'R2D-R/E)&"MV"R%/)/01)T-0")$MR-M#+
/01)SD"0)1%/.0-+"1)S%$D)C/0C"#)a)JL)'"/#+)-Q)/."[)
Gunnes MW et al., British Journal of Cancer (2016) 114, 348356
>M#")/$)/)C-+$
<%0%R%+"))
&/$")
"QQ"C$+
8M+$/%0)
+M#3%3/&)
#/$"+
@D")!/11'Ib-+1"0 R-1"&)-Q)2#%R-#1%/&)Q-&&%C&")
1"C&%0")OT%#$DIR"0-2/M+"P
Hansen, K. R. et al. Hum. Reprod. 2008 23:699-708
4-S"#IR-1"&)-Q)DMR/0)-3/#%/0)_b!)1"C/'
<"$D-1-&-.'
:;<;8;77127;<.53
=>4?<2@;<.,8?2;1,-8A5180;<;8?561,2?8A15@8<-28
/.<21;<612
=B;C/2?D8,-;1<?D802?,1.9<.E28?<;<.?<.,?
=F6185G380;<;8H.A8;E;./;C/2
:;<;8?2/2,<.538<58,12;<280;<;8?2<
=IJ,/6?.538K8L3,/6?.538,1.<21.;8M2#7#82J,/6028
.3A21<./2N
=O5@5723256?80;<;8?2<8<-;<8;9915J.@;<2?8<-28
-2;/<-489596/;<.538A518;8G.0281;37285A8;72?#
<"$D-1-&-.'
P5@9;1;<.E28;3;/4?.?85A8C.5/57.,;//489/;6?;C/2 @502/?
755032??85A8A.<8M,52AA.,.23<85A802<21@.3;<.53Q81%N
@.3.@.?2 5E21A.<<.37
<558;,,61;<28<5872321;/.?2 <5863?22380;<;
<-28@502/8.?8<558,5@9/2J
@.3.@.?2 63021A.<<.37
35<8;,,61;<2823567-8
<-28@502/8.?8<558?.@9/288
<"$D-1-&-.'
R502/8E;/.0;<.538.?8.@951<;3<
<-28-.7-2?<S1;3T208,;30.0;<28,56/08C28;812?6/<85A8
?21230.9.<4
?@;//8,-;372?8.38<-280;<;8,56/08915@5<285<-218
,;30.0;<2?
B-2128;128E;1.56?8<2,-3.U62?
TSA5/0Q8?9/.<8<-280;<;8.3<58$"82U6;/8?6C?2<?
<1;.38538)"VD8<2?<86?.378$"VD8A5182;,-8,-5.,285A8$"V
@502/8E;/.0;<208.A8<-289120.,<.538211518.?863.A51@
?/$/)+"$()
7%.D$)cM/0$%$/$%3")D%+$-&-.%C/&)+$M1%"+
@D")9/&&/C"IA"&+"')_b!)<-1"&
Wallace & Kelsey (2010)
PloS ONE 5(1): e8772,
doi:10.1371/journal.pone.0008772
63/#%/0)#"+"#3"()>-0C"2$%-0)$-)<"0-2/M+"
Wallace & Kelsey (2010) PloS ONE
4"#C"0$/.")-Q)_b!)2-2M&/$%-0)#"R/%0%0.)S%$D)%0C#"/+%0.)/."
Wallace & Kelsey (2010) PloS ONE
!-&&%CM&/#)5"C#M%$R"0$)Q#-R)$D")4--&)/CC-#1%0.)
$-)/.")-Q)R"0-2/M+"
There%is%close%to%100%fold%difference%in%recruitment%
between%the%early%and%late%menopause%groups Wallace & Kelsey, 2010
7]$"#0/&)3/&%1/$%-0
oW?.3785618@502/8;308<-280.?<1.C6<.5385A8@2359;6?;/8;72?8021.E208A15@8<-28
9596/;<.538C;?208X15?92,<SIXLP8,5-51<8M38Y8*D"&'N8
oZ285C<;.38/.3T208@502/?8A518C5<-8;728;<8@2359;6?28;30802,/.3.378[\]8,563<8
G.<-8.3,12;?.378;728
oB-280.?<1.C6<.53?85A85C?21E208;728;<83;<61;/8@2359;6?28;3089120.,<208;728;<8
3;<61;/8@2359;6?28?-5G8,/5?28,53A51@.<48
oB-.?87.E2?86?8.3,12;?208,53A.023,2Q
^# <-;<85618@502/8,5112,</4802?,1.C2?8?5@2<-.378<-;<8.?8.@95??.C/28<58@2;?6128in#
vivo
_# <-;<8;8/;17218<-;38;E21;728[\]8955/8@2;3?8/;<218<-;38;E21;728@2359;6?28M;308
vice#versaN
:29@;33D8];00482<8;/#8%"$!
`5613;/85A8P/.3.,;/8I305,1.35/5748;308R2<;C5/.?@8100M+NQ8I(*!SI(!$D8
05.Q$"#$%$"ab,#%"$!S$%)(
*01%#"C$)R"/+M#"+)-Q)-3/#%/0)#"+"#3"
o^3<.8R6//21.;3 O51@5328M^RON8.?891506,208C48<-2871;36/5?;8,2//?85A8
?@;//8715G.378A5//.,/2?
o^RO8-;?8/.<</28E;1.;<.538;,15??8;308C2<G2238@23?<16;/8,4,/2?8
o^RO8.?8<-28C2?<8,61123</48;E;./;C/28@;1T2185A8<-2836@C2185A8?@;//S
715G.378A5//.,/2?8.38<-285E;14
oFE;1.;38c5/6@28MFcN8
o:2,12;?2?8/;<218.38/.A2
oL38/.328G.<-8<-2802,12;?28.38[\]89596/;<.53
oO495<-2?.?Q8;8/;17285E;148,53<;.3?8;8/;172836@C2185A8[\]?
o^3<1;/8]5//.,/28P563<?8M^]PN
o[5<8,5E21208.38<-.?8<;/T
Kelsey, Anderson et al. Molecular Human Reproduction 18(2): 79-87,
doi:10.1093/molehr/gar059, 2012
;<:)?/$/)+"$
;)3/&%1/$"1)R-1"&)-Q)+"#MR)/0$%I<M&&"#%/0 D-#R-0")Q#-R)C-0C"2$%-0)$-)
R"0-2/M+")
O/)+%0.&")1/$/)+"$)-Q)D"/&$D')Q"R/&"+))O0`ZFKGP)Q#-R)$S"0$')+-M#C"+P)
Kelsey et al. PLoS ONE 2011
;<:()_-#R-.#/R)Q#-R)T%#$D)$-)R"0-2/M+")
@D").#""0)/01)T&M")&%0"+)/#")$D")KY^)/01)XL^)2#"1%C$%-0)&%R%$+)Q-#)$D")R-1"&)
Kelsey et al. PLoS ONE 2011
5"&/$%-0+D%2)T"$S""0);<:)/01)!-&&%CM&/#)
#"C#M%$R"0$
X12S96C21<4Q8><1537895?.<.E28,5112/;<.538M18Y8"#)%N#8^RO8
;308A5//.,6/;1812,16.<@23<8.3,12;?.37
X6C21<;/Q8R5021;<28327;<.E28,5112/;<.538M18Y8S"#!!N#8^RO8
A;//?8;?8A5//.,6/;1812,16.<@23<8,53<.362?8<581.?28MB1;3?.<.538
X-;?2N
X5?<H96C21<;/8M$!8S%!NQ8><15378327;<.E28,5112/;<.538M1Y8
S"#(&N#8^RO81.?2?8;?8]5//.,6/;1812,16.<@23<8A;//?#
X5?<8^728%!842;1?Q8c2148><1537895?.<.E28,5112/;<.538
M1Y"#)+N#8^RO8/2E2/8.?8;875508?61157;<28@;1T2185A802,/.3.378
5E;1.;3812?21E2 Fleming, Kelsey et al. Fertility & Sterility 98(5): 1097-1102,
doi:10.1016/j.rbmo.2012.06.008, 2012
The%normative%validated%model%of%ovarian%volume%throughout%life.
Kelsey TW et al. (2013) Ovarian Volume throughout Life: A Validated Normative
Model. PLoS ONE 8(9): e71465
7]$"#0/&)d/&%1/$%-0)-Q)_b!)/01)6d)<-1"&+
;)R-1"&)$-)2#"1%C$)<"/0)!-&&%C&")?"0+%$')Q-#)
D"/&$D')Q"R/&"+)/."1)JL)NZH)'"/#+
^??6@9<.53Q8;8/;17285E;148,53<;.3?8@5128277?8<-;38;8?@;//8
532
[\]?Q86?28<-28Z;//;,2Sd2/?248@502/8<582?<.@;<28[\]8
9596/;<.53D87.E.378[\]M;72N
c5/6@2Q86?285618@502/8<582?<.@;<28<-285E;1.;38E5/6@2D8
7.E.378c5/6@2M;72N8
X120.,<208R]:M;72N8.?8<-238[\]M;72N80.E.0208C48
c5/6@2M;72N
MZ28-;E28<58;0b6?<8A518<-28915951<.5385A8;8<49.,;/85E;148<-;<8
,53?.?<?85A8,51<.,;/8<.??62N
Fleming, Kelsey et al. Fertility & Sterility 2012
7]$"#0/&)d/&%1/$%-0)-Q)_b!)/01)6d)<-1"&+
McGloughlin, Kelsey et al. Journal of Assisted
Reproduction and Genetics 32(7): 1089-1095,
doi:10.1007/s10815-015-0501-7, 2015
e+%0.)$D")R-1"&+)$-)/++"++)
_b!+)/Q$"#);,d?
MCLAUGHLIN, KELSEY ET AL. HUMAN REPRODUCTION 32
(1): 165-174, DOI:10.1093/HUMREP/DEW260, 2016
40
<-1"&&%0.)$D")-3/#%/0)#"+"#3"
oR5021380;<;S01.E238<2,-3.U62?8;//5G86?8<58021.E28K8E;/.0;<28;72S
12/;<208@502/?
oB-2?28,;38C28<-567-<85A8;?8<-282AA2,<85A83581;0.5S 518,-2@5S
<-21;94
oZ28,;38,5@C.328
$N ;,,61;<289120.,<.53?85A85E;1.;3812?21E28C2A5128<12;<@23<
%N @2;?612@23<?8;A<218<12;<@23<
oB585C<;.38U6;3<.A.2082?<.@;<2?85A8<-282AA2,<85A8<12;<@23<8538/537S
<21@8A21<./.<4
oB-28A.3;/82J;@9/28.?8U6;3<.A.,;<.5385A8<-282AA2,<85A81;0.;<.538538<-28
5E;14 Effect of first line cancer treatment on the ovarian reserve and
follicular density in girls under the age of 18.
Fertility and Sterility 106 (7), 17571762.e1
;."If)1-+"I#"&/$"1)2#"1%C$%-0)-Q)
46*)/Q$"#)#/1%-$D"#/2'
Kelsey, Hua and Wallace, in press
;."If)1-+"I#"&/$"1)2#"1%C$%-0)-Q)
46*)/Q$"#)#/1%-$D"#/2'
Kelsey, Hua and Wallace, in press
!"#$%&%$')2#"+"#3/$%-0)-2$%-0+()"+$/T&%+D"1)
/01)"]2"#%R"0$/&
FERTILITY RISK ASSESSMENT
(Includes Intrinsic and Extrinsic factors)
Pre-pubertal
Testis
biopsy
Pubertal
Able to produce a suitable
semen sample
Post-pubertal
Testis Tissue
Cryopreservation
Experimental Established
Sperm
Cryopreservation
Ovarian Tissue
Cryopreservation
Embryo
Cryo
Pre-pubertal
FEMALEMALE
Patient
Assessment
Intervention
Storage
NO
Testis biopsy/
Gamete extraction
YES
Post-pubertal
Ovarian
stimulation
Partner/
Donor
sperm
Oocyte
Cryo
Ovarian biopsy
A"')Q"/$M#"+)-Q)$D")Z)-2$%-0+)Q-#)
Q"#$%&%$')2#"+"#3/$%-0)Q-#)S-R"0
I@C1458,145912?21E;<.53
=I?<;C/.?-208C6<812U6.128<.@28;308;89;1<321
F5,4<28,145912?21E;<.53
=I?<;C/.?-208C6<812U6.128<.@28;308-51@5328?<.@6/;<.538M?6,,2??81;<289218
55,4<28/5GN8
FE;1.;38<.??628,145912?21E;<.53
=R.3.@;/802/;4
=[58/5G218;728/.@.<
=>617.,;/8915,20612
=^//5G?8A518A6<612802E2/59@23<?
4#%RMR 0-0)0-C"#"
;)4/$%"0$
</#CD)FGJJ)O/.")JL)'"/#+P
8%])R-0$D):\6)-Q)%0$"0+")
2#M#%$%+ -Q)D"#)Q""$
@D#"")R-0$D):\6)Q"3"#E)
0%.D$)+S"/$+E)&"$D/#.'E)
2/&&-#E)2--#)/22"$%$")/01)
S"%.D$)&-++
9%1"+2#"/1)=_)N&-S"#)
C"#3%C/&E)R"1%/+$%0MRE)
/T1-R"0
=/M#/()4#"+"0$/$%-0)47@\>@
7M#-_"$I4:=I>IJ)
%8J8
FIX^ RA
e;0.5<-21;94
[5
e;0.5<-21;94
XIB8
95?.<.E2
XIB88
327;<.E2
TG-1
TG-2
TG-3
%8PFXX
R
*8PFXX
R
%8PFX:^P
*8PFX:^P
CRUK support 400K
Wallace WH. UK Chief Investigator
Anderson RA…Wallace WH. Lancet Diabetes Endocrinol. 2015
5%+V)-Q)%0Q"#$%&%$'
Low risk (<20%) Medium risk High risk (>80%)
ALL
Wilmstumour
Brain tumour
Sx, RT < 24Gy
Soft tissue sarcoma
(stage1)
Hodgkins
Lymphoma HL(Low
stage)
AML
Osteosarcoma
Ewings sarcoma
STS: stage II/III
Neuroblastoma
NHL
Brain tumour
RT>24Gy
HL (High Stage)
Total Body
Irradiation
Pelvic/testes RT
Chemo pre BMT
Metastatic Ewing's
HL (Pelvic RT)
Wallace, Anderson, Irvine. Lancet Oncology 2005
5/1%/$%-0I%01MC"1)-3/#%/0)1/R/."
O6@;3855,4<28
MX1.@510.;/8A5//.,/2N
Üf:!"8g8%8\4
Wallace,%Thomson,%Kelsey.%(2003)%
Human%Reproduction%18M$):%117-
121,%doi:10.1093/humrep/deg016
;."If)1-+"I#"&/$"1)2#"1%C$%-0)-Q)
46*)/Q$"#)#/1%-$D"#/2'
Kelsey, Hua and Wallace, in press
63/#%/0)#"+"#3"()>-0C"2$%-0)
$-)<"0-2/M+"
Anna
Bella
Wall ace &Ke ls e y ( 201 0) Plo S O NE
4#"1%C$%-0)-Q)63/#%/0)5"+"#3")O;<:P
o^3<.8R6//21.;3 O51@5328M^RON8.?8;38.@951<;3<891506,<85A8<-28
;06/<85E;14D891506,208C48<-2871;36/5?;8,2//?85A8?@;//8715G.378
A5//.,/2?
o^RO8-;?8/.<</28E;1.;<.538;,15??8;308C2<G2238@23?<16;/8,4,/2?8
o^RO8.?8<-28C2?<8,61123</48;E;./;C/28@;1T2185A8<-2836@C2185A8
?@;//S715G.378A5//.,/2?8.38<-285E;14
o_6<8<-2128G;?8358E;/.0;<20812A2123,28@502/8A518^RO8;E;./;C/2
Anderson, Nelson, Wallace (2011) Maturitas
;)3/&%1/$"1)R-1"&)-Q)+"#MR)/0$%I<M&&"#%/0
D-#R-0")O;<:P)Q#-R)C-0C"2$%-0)$-)R"0-2/M+")
Kelsey et al. PLoS ONE 2011
=/M#/
EuroNet-PHL-C1
Protocol:
Treatment Group 3 (TG3)
Two cycles of OEPA
Four cycles of COPDAC
or COPP
7/#&')5"+2-0+");++"++R"0$)47@)+C/0
5/1%-$D"#/2')!%"&1)/01)"+$%R/$"1)
1-+"+)$-)-#./0+)/$)#%+V
Anderson RA…Wallace WH. Lancet Diabetes Endocrinol. 2015
!"#$%&%$')2#"+"#3/$%-0)Q-#)2#"I
2MT"#$/&).%#&+
f5<?85A8.@@;<6128A5//.,/2?8M277?N
Z.//8912S96C21<;/85E;1.;38<.??628812?<51282305,1.328A63,<.53h
Z.//8912S96C21<;/85E;1.;38<.??62812?<5128A21<./.<4h
*01MC$%-0)-Q)2MT"#$')T')/M$-.#/Q$)
-Q)C#'-2#"+"#3"1)-3/#%/0)$%++M"
)842;185/08G.<-8IG.37D8.3<23?.E2/48<12;<208G.<-8PB8;308eB
FBP8C2A5128<12;<@23<8,5@@23,20
:2E2/59208XFL8#8[5896C21<;/802E2/59@23<#8L3812@.??.53
*#!842;1?8/;<218M$&#!42;1?N85E;1.;38<.??62812<613208A51896C21<;/8.306,<.53#8
B;33218_*8;308@23?<16;<.538G.<-.38532842;1#
\1;A<8,2;?208<58A63,<.538;A<218$)8@53<-?
>2E21;/842;1?8/;<218?-2812/;9?208;3080.208A15@812,61123<8IG.378?;1,5@;
[582E.023,285A8IZ>8]fL$8.3812@;.3.378?<512085E;1.;38<.??62#
Ernst et al EJC, 2013
*01MC$%-0)-Q)2MT"#$')T')/M$-.#/Q$)
-Q)C#'-2#"+"#3"1)-3/#%/0)$%++M"
oL306,<.5385A896C21<48G.<-82J572356?8?<215.08-51@532?8
2.<-21851;//48518<1;3?S021@;//48.?8G2//82?<;C/.?-20
oB-2812S.@9/;3<;<.5385A85E;1.;38<.??628.38;8
-4921753;05<159-., 23E.153@23<8835<8.02;/
oX5<23<.;/8G;?<285A8;8A.3.<2836@C2185A8721@8,2//?8
oe.?T85A812/;9?28##9;1<.,6/;1/48.38-;2@;<5/57.,;/8
@;/.73;3,.2?8
vThe%patient%(from%UAE)%suffered%from%Thalassemia,%had%
ovarian%tissue%frozen%in%2001%(Leeds,%UK)%at%the%age%of%9%
years%prior%to%bone%marrow%transplantation
vThe%tissue%was%brought%to%Denmark%in%2015%and%
transplanted%back
vThe%patient%conceived%after%IVF%treatment%in%the%UK%and%
give%birth%in%December%2016%
Edinburgh experience in children (< 18 yrs) 1996-2012
63/#%/0)>#'-2#"+"#3/$%-0)f)63/#%/0)
!M0C$%-0
The Lancet Diabetes and Endocrinology 3(7): 556-567,
doi:10.1016/S2213-8587(15)00039-X,2015
JL)'"/#E)2-2M&/$%-0IT/+"1)/0/&'+%+)-Q)
C#%$"#%/)Q-#)-3/#%/0)C#'-2#"+"#3/$%-0
Female cancer patients
age <18 at diagnosis
01/01/1996 - 30/6/2012
n = 410
Offered cryopreservation
n = 34
Tissue cry opr eserved
n = 20
Procedure
declined
n = 13
Procedure
unsuccessful
n = 1
Deceased
n = 1
Not offered cryopreservation
n = 376
Deceased
n = 81
Deceased
= cryopreservation offered.
= reasons for not having tissue cryopreserved.
= patients in study eligible for ovarian function evaluation.
n = 1
n = 4
Poor
communication
n = 1
Uterine
factor
n = 1
Parental
choice
n = 2
To o u nw e ll
n = 9
<12 years old
n = 91
<12 years old
n = 1
Deceased
n = 3
<12 years old
n = 2
Lost to follow-up
n = 1
<12 years old
n = 14 n = 6 n = 141
On COCP
n = 1
Still on
treatment
n = 4
On COCP
n = 17
Insufficient
information on
follow-up
n = 42
Walllace WH et al. 2014 Lancet Oncology
?-)$D")g6QQ"#"1h).#-M2)D/3")/)D%.D"#)2#"3/&"0C")-Q)46*U
Not offered
Offered
>MRM&/$%3")%0C%1"0C")-Q)46*
15-year probability 35% [95% CI 10–53] vs 1% [0–2] p<0.0001
Hazard ratio 56.8 [95% CI 6.2–521.6] at 10 years
Wallace WH et al., 2014. Lancet Oncology 15(10): 1129-1136, doi:1 0.1016/S1470-2045(14)70334-1
>-0C&M+%-0
FE;1.;38,145912?21E;<.538G;?85AA21208<58)V85A85618
9;<.23<?D8;308921A51@208.38!V
B-28915,206128G;?8?;A28;308G.<-56<8,5@9/.,;<.53?
[589;<.23<?8-;E28;?T208A51812S.@9/;3<;<.5385A8<-2.18<.??628H
<580;<28
^//89;<.23<?8G-58-;E28<-6?8A;1802E2/59208912@;<6128
5E;1.;38.3?6AA.,.23,48G2128.023<.A.2082J,29<853289;<.23<
B-28I0.3C617-8>2/2,<.538P1.<21.;8-;E28915E208<58C28-2/9A6/8
.38?2/2,<.378<-5?289;<.23<?8;<8-.7-2?<81.?T85A8XFL
Wallace WH et al., 2014. Lancet Oncology 15(10): 1129-1136, doi:1 0.1016/S1470-2045(14)70334-1
@D")-0.-%0.)CD/&&"0."+
X15E.028A21<./.<48,563?2/.378<58;//84563789;<.23<?8G.<-8
,;3,21
P145912?21E285E;1.;38<.??628A15@8<-281.7-<8M-.7-81.?TN8
9;<.23<?
:2A.328<-28?6,,2??81;<285A8<-28915,20612?8MA518,-./01238
;?8G2//8;?8;06/<?N
:2E2/598Lc\aR8;?8;8?;A28;/<213;<.E28<-1567-8C;?.,8
12?2;1,-
<"$/2D/+")**)--C'$"+)Q#-R)
DMR/0M0%&/R%0/# Q-&&%C&"+).#-S0)%0)/)
RM&$%I+$"2)CM&$M#")+'+$"R
:2E2/59@23<85A8-6@;38
55,4<2?8A15@8
91.@510.;/a63./;@.3;1 ?<;72?8
<5812?6@9<.5385A8@2.5?.?8
MR2<;9-;?28LLN8;3082@.??.538
5A8;895/;18C5048G;?8;,-.2E208
G.<-.38;8?216@8A1228@6/<.S
?<298,6/<6128?4?<2@#
McLaughlin M et al. Molecular Human Reproduction, pp. 1–8, 2018
;CV0-S&"1."R"0$+
e.,-;108^3021?53
:;E.08B8_;.10
B5@8d2 /?24
IE2/438B2/A21
R;1.28R,f;67-/;3
^/.,28\15E28>@.<-
\251728\;/2;
e508R.<,-2//
f56.?28_;<-
P-1.?8d2/3;1
^372/;8I07;1
R;1T8_1567-;@
]1;?218R6315
@D/0V)B-M
ResearchGate has not been able to resolve any citations for this publication.
  • R A Anderson
Anderson RA et al. Human Reproduction 33(7): 1281-1290, doi:10.1093/humrep/dey216